TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02400931

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mask ventilation
Description: In mask ventilation group, rocuronium of 0.6 mg/kg will be administered after the loss of consciousness. Mask ventilation wil be performed until there is no response on the train-of-four stimulus. No mask ventilation - In no mask ventilation group, rocuronium of 1.2 mg/kg will be administered after the loss of consciousness. Tracheal intubation will be performed after confirmation of no response on the train-of-four stimulus. The mask ventilation will not be performed before the tracheal intubation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no mask ventilation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Study: NCT01370343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532 alone
Description: a single dose of 150 mg PF-04991532, fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532 + cyclosporine
Description: a single dose of 150 mg PF-04991532 + a single dose of 600 mg cyclosporine, fasted
Study: NCT02329639

Intervention type: GENETIC
Intervention: genetic interaction analysis
Description: VEGFR-2 rs11133360/IL-8 rs4073 genetic interaction analysis

Intervention type: GENETIC
Intervention: genetic interaction analysis
Description: VEGFR-2 rs11133360/IL-8 rs4073 genetic interaction analysis
Study: NCT01019213

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Septal pacing
Description: Septal lead activated

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: His lead activated
Description: His lead will be activated 80 ms before septal lead
Study: NCT03589625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solar Suitcase
Description: The intervention is a Solar Suitcase. The Solar Suitcase comes with: 2 LED lights, 1 battery, 1 aluminum glass 100 watt solar panel, 2 rechargeable LED headlamps, 1 universal cell phone charger, 1 USB adapter, 1 fetal Doppler, 1 AA/AAA battery charger and expansion box (provides 2 additional lights).~Installers will teach health workers how to use and maintain the Solar Suitcase on the day of installation. Within one week following installation, the contractor will contact the facility over the phone and/or in-person to check if there are any problems with the Suitcase. Additional checks will be made to ensure the solar suitcase is functioning and being used properly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solar Suitcase
Description: The intervention is a Solar Suitcase. The Solar Suitcase comes with: 2 LED lights, 1 battery, 1 aluminum glass 100 watt solar panel, 2 rechargeable LED headlamps, 1 universal cell phone charger, 1 USB adapter, 1 fetal Doppler, 1 AA/AAA battery charger and expansion box (provides 2 additional lights).~Installers will teach health workers how to use and maintain the Solar Suitcase on the day of installation. Within one week following installation, the contractor will contact the facility over the phone and/or in-person to check if there are any problems with the Suitcase. Additional checks will be made to ensure the solar suitcase is functioning and being used properly.
Study: NCT02059616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg
Description: Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg
Description: Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg
Description: Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10mg
Description: Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10mg
Description: Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10mg
Description: Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil 8mg
Description: Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil 8mg
Description: Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil 8mg
Description: Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16mg
Description: Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16mg
Description: Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16mg
Description: Daily oral administration for 8 weeks
Study: NCT02076568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education - Diabetes and Partnership
Description: Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Partnership was created. The module covers specific and detailed aspects of the topic partnership such as dealing with hypoglycemia, late complications, and talking about diabetes in a relationship. With this module, a more comprehensive education of patients with specific interest in these topics is possible.
Study: NCT02476435

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS
Description: Strong electromagnetic fields (\~2Tesla) generated briefly but repetitively (1Hz) applied for 30mins, in five sessions per week for 3 weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo rTMS
Description: Placebo electromagnetic fields generated briefly but repetitively applied for 30mins, in five sessions per week for 3 weeks
Study: NCT02920710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection
Description: * Initial treatment with 80 units daily for ten days (induction phase)~* Maintenance treatment with 80 units twice weekly (maintenance phase)
Study: NCT01643499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03117582

Intervention type: OTHER
Intervention: Stool specimen
Description: The following stool specimen will be collected for this study:~1. 4, 3mL stool specimen from patient~2. 1, 25mL stool aliquot from donor
Study: NCT02611518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911
Description: JNJ-54861911 will be administered at a dose of 25 mg once daily from Day 8 to Day 17 (in panel 1), Day 8 to 16 (in panel 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911
Description: JNJ-54861911 will be administered at a dose of 25 mg once daily from Day 8 to Day 17 (in panel 1), Day 8 to 16 (in panel 2).
Study: NCT02876016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional MRI
Description: locate the cerebral bases in functional imaging
Study: NCT00824642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Applied 45 minutes prior to exercise

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Applied 45 minutes prior to exercise

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo TENS applied prior to exercise
Study: NCT03329482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PULSE ULTRASOUND
Description: For group A, The PUS group received pulse mode of ultrasound (sonoplus 490s), with frequency of 1MHZ and intensity of 1.5w/cm according to Ebadi et al 10). Grey's formula was used to estimate the duration of ultrasound (US) for each patient 21). The average local exposure time was one minute and the effective radiating area of the transducer head was 5 cm2. For a patient with an area of low back pain of 40 cm2, the required total treatment time was: 1 min × (40 cm2/5 cm2) = 8 minutes. US was applied using slow circular movements, with the transducer head placed over the painful paravertebral low back region and Lofnac gel used as coupling medium.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KNEADING MASSAGE
Description: Kneading massage was done with the two hands maintaining a slow circular compression of soft tissues against underlying bone. Pressure was applied as the hands moved proximally, continuously maintaining a contact with the skin, according to Goat22). Lofnac gel was used as a coupling medium for the massage. This was done for an approximately ten and 12 minutes.
Study: NCT00909649

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fibrin glue in breast surgery
Description: fibrin glue 8 ml in the bed after modified radical mastectomy in fibrin treated group
Study: NCT00291954

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-AS02V
Description: HB-AS02V (20µg HBsAg) will be administered at Month 0 and 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBVAXPRO vaccine
Description: HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0 and 1
Study: NCT03762772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF/EVG Vaginal Insert
Description: 1 combination vaginal insert (20mg TAF/16mg EVG)
Study: NCT02582424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PD-L0101
Description: 92% EPA+6 mg ATX+50 mg TCT GG BID

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01951807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Study: NCT03358446

Intervention type: OTHER
Intervention: A group
Description: The optimal range of leg abduction was defined as the range without overlap in A group and the range presenting that the overlap was less-than half of the diameter of femoral vein in S group.~A1 angle defined the point that the femoral vein and artery started non-overlapping interval when increasing the angle of the leg in the A group and the A2 angle is defined the point that the femoral vein and artery ended non-overlapping interval.

Intervention type: OTHER
Intervention: S group
Description: B1 is the angle at which the overlap starts at the half of the femoral vein radius when increasing the angle of the leg in the S group, B2 is the angle at which overlap starts at half or more of the femoral vein radius again. In the range of B1 and B2 angles, they are overlapped by half or less of the femoral vein radius.
Study: NCT02095717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Taxotere
Study: NCT03190850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The device in which the breathing exercises will be performed will be adjusted with progressive loading aiming to improve muscular strength

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The device in which the breathing exercises will be performed will not be adjusted with progressive loading.
Study: NCT00973505

Intervention type: DRUG
Intervention: Aromatase Inhibitor(Femara or Arimidex)
Description: Femara(Letrozole) 2.5mg 1tab qd, Arimidex(Anastrozole) 1mg 1tab qd
Study: NCT05673746

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: acupuncture administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment of physician choice, according to the standard of care
Description: treatment of physician choice, according to the standard of care for the treatment of chemotherapy-induced peripheral neuropathy, including neuropathic pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment of physician choice, according to the standard of care
Description: treatment of physician choice, according to the standard of care for the treatment of chemotherapy-induced peripheral neuropathy, including neuropathic pain
Study: NCT00068458

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium-Rich Diet
Description: 1,200 - 2,500 mg/day. 6 month intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2: Exercise + Calcium-Rich Diet
Description: Dietary counseling + material promoting strength training an aerobic activity + a calcium intake of 1,200 - 2,500 mg/day. 6 month intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise + Fruit & Vegetable, Low Fat + Calcium Diet
Description: 1,200 - 2,500 Calcium intake per day. 6 month intervention period.
Study: NCT02776475

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sacral neuromodulation device turned off
Description: Each patient will be to have the sacral neuromodulation device turned off for four consecutive weeks.
Study: NCT01485406

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2830930A
Description: 1 dose administered intramuscularly

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix™
Description: 1 dose administered intramuscularly
Study: NCT01695954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Pitavastatin 2 mg tablets taken at bedtime in Arm A and in the morning in Arm B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Pitavastatin 2 mg tablets taken at bedtime in Arm A and in the morning in Arm B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir 400 mg tablets x 2 taken daily in Arm B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100 mg tablets taken daily in Arm B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Efavirenz 600 mg tablets taken at bedtime in Arm A
Study: NCT02614235

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pocket-ECG III system
Description: Continuous cardiac telemetry until diagnosis or a maximum of two months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pocket-ECG III system
Description: Continuous cardiac telemetry until diagnosis or a maximum of two months
Study: NCT01363492

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Replagal (agalsidase alfa)
Description: 0.2 mg/kg administered over 40 minutes every other week (EOW)
Study: NCT02611518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be administered as a single oral 500 mg on Day 1 and Day 14.
Study: NCT02745041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate
Description: Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM guided treatment algorithm \[FIBTEM ≤ A5 10mm\]~FIBTEM A5 0mm (Flat Line) = 6g FC FIBTEM A5 1 - 4mm = 5g FC FIBTEM A5 5 - 6mm = 4g FC FIBTEM A5 7 - 8mm = 3g FC FIBTEM A5 9 - 10mm = 2g FC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryoprecipitate
Description: Fibrinogen replacement using Cryoprecipitate as per ROTEM guided treatment algorithm \[FIBTEM A5 ≤ 10mm\]~FIBTEM A5 0mm (Flat Line) = 20 Units Cryo FIBTEM A5 1- 4mm = 16 Units Cryo FIBTEM A5 5 - 6mm = 14 Units Cryo FIBTEM A5 7 - 8mm = 10 Units Cryo FIBTEM A5 9 - 10mm = 8 Units Cryo
Study: NCT05695404

Intervention type: PROCEDURE
Intervention: Segmentectomy
Description: Lung resection

Intervention type: PROCEDURE
Intervention: Segmentectomy
Description: Lung resection
Study: NCT02315417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gevokizumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gevokizumab open-label
Study: NCT00252317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Captopril and Trandolapril
Description: Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Captopril and Trandolapril
Description: Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Captopril Test Dose and Trandolapril
Description: Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Captopril Test Dose and Trandolapril
Description: Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
Study: NCT03903913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1226
Description: The drug product S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) nebulized with a medical gas mixture containing CO2. The PFOB component remains the same but the medical gas component contains 4%, 8% or 12% CO2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1226
Description: The drug product S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) nebulized with a medical gas mixture containing CO2. The PFOB component remains the same but the medical gas component contains 4%, 8% or 12% CO2.
Study: NCT00917137

Intervention type: PROCEDURE
Intervention: TBNA + transbronchial lung biopsy + bronchial washing
Study: NCT02048852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Nicotine Content- Non Menthol
Description: Switch from own brand of cigarette to a research cigarette with a Reduced Nicotine Content of 0.07mg nicotine yield without menthol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Nicotine Content- Menthol
Description: Switch from own brand of cigarette to Reduced nicotine level of each research cigarette to 0.07mg nicotine yield with Menthol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Nicotine Content- Menthol
Description: Allow own brand of Conventional Nicotine-Menthol Cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Nicotine Content- Non Menthol
Description: Switch from own cigarette to a research cigarette which contains Conventional Nicotine yield.
Study: NCT03420157

Intervention type: OTHER
Intervention: Focus Group
Description: Focus Group of 2 hours. Women will be asked to give their opinion about the communication media of the vaginal self-sampling kit.
Study: NCT01691079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ipratropium bromide
Description: Inhaled ipratropium bromide administered before exercise.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo administered before exercise.
Study: NCT00274469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: 500 mg intramuscular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: 1 mg oral tablet
Study: NCT02139436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FES-row-training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arms-only-row training
Study: NCT03296072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.254% w/w sodium fluoride and 5% KNO3
Description: Dentifrice containing 0.254% w/w sodium fluoride (1150 ppm fluoride) and 5% KNO3; plus 0.25% PVM/MA copolymer and 2.5% sodium lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 millilitres \[mL\] of tap water for 10 seconds before expectorating again.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.454% w/w stannous fluoride
Description: Dentifrice containing 0.454% w/w stannous fluoride (1100 ppm fluoride). Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% KNO3
Description: Fluoride free placebo dentifrice containing 5% KNO3 (0 ppm fluoride), 0.25% PVM/MA copolymer and 2.5% lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
Study: NCT02139436

Intervention type: OTHER
Group type: OTHER
Intervention: Time Control
Study: NCT03440346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Few-foods diet
Description: The few-foods diet (FFD) is followed for 5-weeks preceded by a 1-week transition period during which the child's eating pattern will be gradually adjusted. The diet consists of rice, meat (turkey and lamb), a range of vegetables, pear, rice milk with added calcium and water, and is complemented with foods such as potatoes, fruits, corn, some sweets and wheat, which are allowed in small quantities only. Normal quantities of vegetables, rice and meat are allowed every day. If necessary the diet will be adjusted to avoid foods that the child dislikes or has cravings for. If the child does not respond to the initial FFD, i.e. no change in behaviour after the first two weeks, interim adjustments to the FFD will be made in consultation with the parents.
Study: NCT00767793

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One drop in each eye every 12 hours for seven days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS117548
Description: One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS117548
Description: One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS117548
Description: One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days